Tomáš Doležal, MD, PhD (CZ)
The founder and director of Intitute of Health Economics and Technology Assessment (iHETA) in Czech Republic.
Graduated as physician trained in internal medicine and done his PhD thesis in Clinical Pharmacology at Charles University in Prague.
He is experienced in pharmacoepidemiology, health outcomes research and pharmacoeconomics with publishing and presenting in the ISPOR and HTAi meetings.
From 2008-2009 he acted as a head of pricing and reimbursement department fo State Institute of Drug Control (SUKL), regulatory body responsible for drug´s HTA in Czech Republic.
He is chairman of Czech Society of Pharmacoeconomics (ISPOR Chapter) and Editor-in-Chief of the FARMAKOTERAPIE journal.
He is also the scientific director of VALUE OUTCOMES, contract research company providing services in market access and outcomes research.